Source: International Congress 2017 – Asthma: mechanisms and treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Jusufovic (Tuzla, Bosnia and Herzegovina). Curcumin as an Add-on Therapy of Moderate Partially Controlled Asthma. 4695

Member's Comments

No comment yet.

Related content which might interest you: Curcumin Improves Therapy of Moderate Partially Controlled Asthma: Placebo-controlled, single blind study Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Long-Acting Beta Agonist Asthma Pharmacogenetic Loci Identified in Two Multi-Racial Asthma Clinical Trials Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Real-world Omalizumab and Mepolizumab treated Difficult Asthma Phenotypes and their Clinical Outcomes Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Safety and Efficacy of Omalizumab in Elderly Patients with Uncontrolled Allergic Asthma. Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Comparison of Clinical Efficacy and Safety between ultraLABAs and ultraLAMAs in Patients with COPD: A Systemic Review with a Meta-Analysis of Randomized Controlled Trials Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Safety and Tolerability of Combination Therapy with Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis: A Multicenter, Retrospective, Observational Study in Japan Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Late Breaking Abstract - TriOptimize VIII – Improvement of Lung Function with Extrafine Single Inhaler Triple Therapy – Analysis of Response Patterns by Prior Treatment from a Real-World Study. Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Aerobic Exercise Improves Asthma Phenotype in a Model of Severe Asthma: Involvement of Kinins Source: Virtual Congress 2021 – Environmental and lifestyle impacts on chronic lung disease Year: 2021 Assessment of Efficacy Omalizumab Retreatment in Patients With Severe Asthma Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Nebulized Ipratropium Bromide Protects against Tracheal and Bronchial Secretion during Bronchoscopy:A Randomized Controlled Trial Source: International Congress 2019 – Interventional pulmonology: diagnostic techniques and obstructive airway disease Year: 2019 Interval Exercise Training in Poorly Controlled Asthma: Preliminary Clinical Trial Results Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Dupilumab Effect on Lung Function in Patients With Uncontrolled, Moderate-to-Severe Asthma With an Allergic Phenotype Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Does a Tailored Intervention to Promote Adherence in Patients with Chronic Lung Disease Affect Exacerbations? Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019 The effect of Corticophobia on Inhaled Corticosteroid Treatment Compliance In Adults with Asthma Source: International Congress 2018 – Asthma analysis Year: 2018 Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD Year: 2018 Exacerbations and Eosinophil Levels in ACCESS Cohort Participants Prescribed Inhaled Triple Therapy Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 FENO Guided Therapy in Asthma: A Non-inferiority Study Source: International Congress 2019 – Eosinophils and FeNO in airway diseases Year: 2019 Effectiveness of Nebulized Budesonide in Iranian Patients with Asthma Attack Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Late Breaking Abstract - Clinical Efficacy and Safety of Macitentan Transitioned from Bosentan in Patients with Pulmonary Arterial Hypertension Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension Year: 2018 Late Breaking Abstract - Standard-of-Care Asthma Controller Regimen Reduction with Benralizumab Treatment: ANDHI In Practice Study Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021